Adults: Each vial or syringe (approx. 300mcg) prevents sensitization to a volume of up to 15mL of Rh positive red blood cells. Administer IM at 28 weeks of gestation, within 72 hours of an Rh incompatible delivery, miscarriage, abortion, or transfusion accident.

Children: Not recommended.

Also: BAYRHO-D MINI-DOSE Rx

[Rh.sub.0](D) immune globulin human 50mcg; for IM inj.

Indications: Prevention of [Rh.sub.0](D) sensitization following termination of pregnancies up to 12 weeks gestation.

Indications: Prevention of isoimmunization in non-sensitized [Rh.sub.0](D) negative women during pregnancy and in appropriate obstetrical conditions, unless the fetus or father is known to be [Rh.sub.0](D) negative. Prevention of isoimmunization in [Rh.sub.0](D) negative individuals transfused with [Rh.sub.0](D) positive blood products.

Indications: Prevention of isoimmunization of [Rh.sub.0](D) negative women during spontaneous or induced abortion of [less than or equal to] 12 weeks' gestation when mother is not sensitized to [Rh.sub.0](D) antigen and father is not known to be [Rh.sub.0](D) negative.

Adults: Postabortion or miscarriage of up to 12 weeks gestation: 1 syringe IM within 3hrs of spontaneous or induced abortion or within 72hrs following termination of pregnancy.

Adults: Each vial or syringe (approx. 300mcg) prevents sensitization to a volume of up to 15mL of Rh positive red blood cells. Administer IM at 28 weeks of gestation, within 72 hours of an Rh incompatible delivery, miscarriage, abortion, or transfusion accident.

Children: See literature.

Also: MICRhoGAM Rx

[Rh.sub.0](D) immune globulin human 50mcg; for IM inj.

Indications: Prevention of [Rh.sub.0](D) sensitization following termination of pregnancies up to 12 weeks gestation.

Indications: Suppression of Rh isoimmunization in non-sensitized [Rh.sub.0](D) negative women during pregnancy and in appropriate obstetrical conditions, unless the fetus or father is known to be [Rh.sub.0](D) negative. Suppression of Rh isoimmunization in [Rh.sub.0](D) negative individuals transfused with [Rh.sub.0](D) positive blood products.

Indications: Suppression of Rh isoimmunization in nonsensitized [Rh.sub.0](D) negative women in appropriate obstetrical conditions, unless the fetus or father is known to be [Rh.sub.0](D) negative. Suppression of Rh isoimmunization in [Rh.sub.0](D) negative females after accidental transfusion of [Rh.sub.0](D) positive blood products.